XBRANE Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.20 |
| 52 Week High | SEK 18.84 |
| 52 Week Low | SEK 0.13 |
| Beta | 0.99 |
| 11 Month Change | -2.46% |
| 3 Month Change | 15.25% |
| 1 Year Change | -98.64% |
| 33 Year Change | -99.82% |
| 5 Year Change | -99.40% |
| Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely
Sep 30
Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12Shareholder Returns
| XBRANE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.2% | -5.8% | -2.1% |
| 1Y | -98.6% | 14.3% | 10.8% |
Return vs Industry: XBRANE underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: XBRANE underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| XBRANE volatility | |
|---|---|
| XBRANE Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: XBRANE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: XBRANE's weekly volatility has decreased from 30% to 13% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 65 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANE fundamental statistics | |
|---|---|
| Market cap | SEK 310.49m |
| Earnings (TTM) | -SEK 304.77m |
| Revenue (TTM) | SEK 199.81m |
1.5x
P/S Ratio-1.0x
P/E RatioIs XBRANE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANE income statement (TTM) | |
|---|---|
| Revenue | SEK 199.81m |
| Cost of Revenue | SEK 76.19m |
| Gross Profit | SEK 123.62m |
| Other Expenses | SEK 428.39m |
| Earnings | -SEK 304.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 61.87% |
| Net Profit Margin | -152.53% |
| Debt/Equity Ratio | 47.7% |
How did XBRANE perform over the long term?
See historical performance and comparison